It's out of favour for a reason. No CDFA approval in sight is a big set back to its growth profile. How much stock did BAL say they had in China that could be sold after the 1/1/2018 cut-off for offline sales? It must be getting awfully close before that 15% (I think) of total BAL revenue goes to $0 and needs to be made up with sales elsewhere just to maintain flat growth.
The politics surrounding the acquisition of CFDA approval is also a worry. For example, if the company applying for approval is partly owned by a Chinese entity it reduces the time frame for approval substantially.
The gap at $10.98 is so close now it would be a disservice if it didn't fill.
- Forums
- ASX - By Stock
- BAL
- $12 here we are
$12 here we are, page-17
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online